Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine Hydrochloride
2. Dapiprazole Hydrochloride
3. Remydrial
4. Rev-eyes
1. 72822-12-9
2. Dapiprazol
3. Dapiprazole [inn]
4. Glamidolo
5. Reversil
6. Remydrial
7. Dapiprazole (inn)
8. 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
9. 5rnz8gjo7k
10. 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
11. Chebi:51066
12. 72822-12-9 (free Base)
13. Dapiprazol [german]
14. Dapirazolum
15. Dapirazol
16. Dapirazol [inn-spanish]
17. Dapirazolum [inn-latin]
18. 1,2,4-triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-
19. Dapiprazolum
20. 1-(2-methylphenyl)-4-(2-{5h,6h,7h,8h-[1,2,4]triazolo[4,3-a]pyridin-3-yl}ethyl)piperazine
21. Unii-5rnz8gjo7k
22. Dapiprazole [mi]
23. Dapiprazole [vandf]
24. Dapiprazole [who-dd]
25. Schembl152543
26. Gtpl7155
27. Zinc1246
28. Chembl1201216
29. Dtxsid90223140
30. Hy-a0142
31. Akos024463973
32. Db00298
33. 3-(2-(4-(o-tolyl)piperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
34. Ncgc00262927-03
35. 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
36. Db-055682
37. Cs-0017462
38. Ft-0603131
39. D07775
40. 822d129
41. L000681
42. Q901963
43. 3-(2-(4-o-tolylpiperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
44. 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl))-s-triazolo(4,3-a)pyridine
| Molecular Weight | 325.5 g/mol |
|---|---|
| Molecular Formula | C19H27N5 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 325.22664588 g/mol |
| Monoisotopic Mass | 325.22664588 g/mol |
| Topological Polar Surface Area | 37.2 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 395 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
FDA Label
Dapiprazole is an alpha-adrenergic blocking agent. It produces miosis by blocking the alpha-adrenergic receptors on the dilator muscle of the iris. Dapiprazole produces no significant action on ciliary muscle contraction and thus, there are no changes in the depth of the anterior chamber of the thickness of the lens. It does not alter the IOP either in normal eyes or in eyes with elevated IOP. The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises.
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
S - Sensory organs
S01 - Ophthalmologicals
S01E - Antiglaucoma preparations and miotics
S01EX - Other antiglaucoma preparations
S01EX02 - Dapiprazole
Absorption
Systemic absorption is negligible.
Dapiprazole acts through blocking the alpha1-adrenergic receptors in smooth muscle. It produces miosis through an effect on the dilator muscle of the iris and does not have any significant activity on ciliary muscle contraction and, therefore does not induce a significant change in the anterior chamber depth or the thickness of the lens.
Global Sales Information
Market Place
ABOUT THIS PAGE
50
PharmaCompass offers a list of Dapiprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dapiprazole manufacturer or Dapiprazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapiprazole manufacturer or Dapiprazole supplier.
PharmaCompass also assists you with knowing the Dapiprazole API Price utilized in the formulation of products. Dapiprazole API Price is not always fixed or binding as the Dapiprazole Price is obtained through a variety of data sources. The Dapiprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dapiprazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dapiprazole, including repackagers and relabelers. The FDA regulates Dapiprazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dapiprazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dapiprazole supplier is an individual or a company that provides Dapiprazole active pharmaceutical ingredient (API) or Dapiprazole finished formulations upon request. The Dapiprazole suppliers may include Dapiprazole API manufacturers, exporters, distributors and traders.
Dapiprazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dapiprazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dapiprazole GMP manufacturer or Dapiprazole GMP API supplier for your needs.
A Dapiprazole CoA (Certificate of Analysis) is a formal document that attests to Dapiprazole's compliance with Dapiprazole specifications and serves as a tool for batch-level quality control.
Dapiprazole CoA mostly includes findings from lab analyses of a specific batch. For each Dapiprazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dapiprazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Dapiprazole EP), Dapiprazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dapiprazole USP).
